Efficacy of autologous platelet-rich plasma intradiscal injection in the treatment of discogenic low back pain

Abstract

Objective To investigate the efficacy of intradiscal injection of autologous platelet-rich plasma (PRP) in the treatment of discogenic low back pain (DLBP). b>Methods A retrospective analysis of clinical data from 47 DLBP patients treated at No.908 Hospital of Joint Logistics Support Force from January 2022 to June 2023 was conducted. Patients were divided into a PRP combined with celecoxib capsule treatment group (experimental group, n=16) and a celecoxib capsule monotherapy group (control group, n=31) based on the treatment method. The visual analogue scale (VAS) of low back pain and Oswestry disability index (ODI) scores were recorded before treatment, at 1 week, 1 month, and 6 months after treatment. Results VAS scores and ODI scores in the experimental group gradually decreased over time; the VAS scores and ODI scores in the control group decreased at 1 week after treatment compared to before treatment, but then showed a gradual upward trend. The VAS scores and ODI scores in the experimental group were lower than those in the control group at 1 month and 6 months after treatment (P＜0.05). Conclusion he long-term efficacy of autologous PRP combined with celecoxib capsule in treating DLBP is superior to that of celecoxib capsule monotherapy and can be considered as an effective treatment for DLBP.

Keywords

• platelet-rich plasma
• discogenic low back pain
• celecoxib
• intradiscal injection